Status:
TERMINATED
Zalutumumab With or Without Irinotecan Chemotherapy in Cetuximab-Refractory Colorectal Cancer
Lead Sponsor:
Genmab
Conditions:
Colorectal Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
The purpose of this trial is to determine the safety and efficacy of Zalutumumab alone or in combination with Irinotecan for the treatment of patients with Colorectal Cancer
Eligibility Criteria
Inclusion
- Males and Females age ≥ 18 years
- Confirmed diagnosis of CRC
- Documented disease progression
- Failure and/or intolerance to standard chemotherapy
Exclusion
- Prior treatment with anti-EGFR antibodies other than cetuximab
- Expected survival \< 3 months
- Clinical significant cardiac disease and/or uncontrolled medical conditions
Key Trial Info
Start Date :
April 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2009
Estimated Enrollment :
9 Patients enrolled
Trial Details
Trial ID
NCT00677924
Start Date
April 1 2008
End Date
April 1 2009
Last Update
July 18 2023
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Institut Jules Bordet
Brussels, Belgium, 1000
2
Hospital Erasme
Brussels, Belgium, 1070
3
St-Luc University Hospital
Brussels, Belgium, 1200